Novo Nordisk is applying for an expanded US label for its long-acting insulin Tresiba, hoping to gain an upper hand on Sanofi's older rival Lantus. Its data submitted to the FDA shows that ...

A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir, arguing that it could leave some diabetics without an ...

Patients with differing levels of insulin resistance and ß-cell reserve may respond differently to self-monitoring and changes in diabetes control regimens. The true impact of self-monitoring ...

The top of executive of Novo Nordisk told a Senate panel Tuesday it was a "difficult choice" to discontinue the long-acting ...